Literature DB >> 2434841

Monoclonal antibodies to the major Lolium perenne (rye grass) pollen allergen Lol p I (Rye I).

C R Kahn, D G Marsh.   

Abstract

Thirteen monoclonal antibodies (MAbs) were produced against Lol p I (Rye I), the major Lolium perenne (rye grass) pollen allergen. Spleen cells from A/J and SJL mice immunized with highly purified Lol p I (Lol I) were allowed to fuse with cells from the non-secreting Sp2/0-Ag14 myeloma cell line. Each MAb was analyzed for antigenic specificity by radioimmunoassay (RIA) using 125I-Lol I. The epitope specificities of seven of the MAbs were examined by competitive binding against a labelled standard MAb for the Lol I antigen (Ag). The dissociation constant, Kd, of one MAb (No. 3.2) that was studied most extensively was determined by double Ab RIA to be 3.5 X 10(-6) L/M. This MAb recognized the related 27,000-30,000 Group I glycoproteins found in the pollens of nine other species of grass pollens tested, including weak binding to Bermuda grass Group I (Cyn d I), which by conventional analysis using polyclonal anti-Lol I serum shows no detectable binding. Monoclonal antibody No. 3.2 was coupled covalently to Sepharose 4B and used to prepare highly purified Lol I from a partially purified rye pollen extract. Finally, an RIA was developed which permitted the analysis of the Group I components in rye grass and nine other grass pollen species. The latter assay is likely to prove useful in the standardization of grass pollen extracts according to their Group I contents.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 2434841     DOI: 10.1016/0161-5890(86)90013-1

Source DB:  PubMed          Journal:  Mol Immunol        ISSN: 0161-5890            Impact factor:   4.407


  7 in total

1.  Epitope specificity of IgE antibodies to a major allergen (Cry j 1) of Japanese cedar pollen in sera of humans and monkeys with pollinosis.

Authors:  M Sakaguchi; M Hashimoto; H Nigi; H Yasueda; Y Takahashi; M Watanabe; T Nagoya; Y Taniguchi; M Kurimoto; S Inouye
Journal:  Immunology       Date:  1997-06       Impact factor: 7.397

2.  Isolation of cDNA encoding a newly identified major allergenic protein of rye-grass pollen: intracellular targeting to the amyloplast.

Authors:  M B Singh; T Hough; P Theerakulpisut; A Avjioglu; S Davies; P M Smith; P Taylor; R J Simpson; L D Ward; J McCluskey
Journal:  Proc Natl Acad Sci U S A       Date:  1991-02-15       Impact factor: 11.205

3.  Cellular localization of water soluble, allergenic proteins in rye-grass (Lolium perenne) pollen using monoclonal and specific IgE antibodies with immunogold probes.

Authors:  I A Staff; P E Taylor; P Smith; M B Singh; R B Knox
Journal:  Histochem J       Date:  1990-05

4.  Recombinant pollen allergens from Dactylis glomerata: preliminary evidence that human IgE cross-reactivity between Dac g II and Lol p I/II is increased following grass pollen immunotherapy.

Authors:  A M Roberts; R Van Ree; S M Cardy; L J Bevan; M R Walker
Journal:  Immunology       Date:  1992-07       Impact factor: 7.397

5.  Analysis of conformational and sequential IgE epitopes on the major allergen Cry j 2 of Japanese cedar (Cryptomeria japonica) pollen in humans by using monoclonal antibodies for Cry j 2.

Authors:  Kazuki Miyaji; Terumi Yurimoto; Akemi Saito; Hiroshi Yasueda; Yukari Takase; Hidekatsu Shimakura; Noriaki Okamoto; Akio Kiuchi; Saburo Saito; Masahiro Sakaguchi
Journal:  J Clin Immunol       Date:  2013-03-16       Impact factor: 8.317

6.  High-density IgE recognition of the major grass pollen allergen Phl p 1 revealed with single-chain IgE antibody fragments obtained by combinatorial cloning.

Authors:  Christoph Madritsch; Elisabeth Gadermaier; Uwe W Roder; Christian Lupinek; Rudolf Valenta; Sabine Flicker
Journal:  J Immunol       Date:  2015-01-30       Impact factor: 5.422

7.  A proteomic style approach to characterize a grass mix product reveals potential immunotherapeutic benefit.

Authors:  Alan Bullimore; Nicola Swan; Wemimo Alawode; Murray Skinner
Journal:  World Allergy Organ J       Date:  2011-09-03       Impact factor: 4.084

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.